Meta AnalysisID 112
薄荷油补充剂对肠易激综合征的效果：随机对照试验的系统评价与Meta分析
CRD42020216021
What are the effects of peppermint oil compared to placebo on symptoms, stool consistency and frequency, and quality of life, in adults with irritable bowel syndrome?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 112
- Evidence Id
- 8670
- Core Evidence Id
- 8670
- Source Meta Analysis Id
- 100
- Herb2 Meta Analysis Id
- HBMA000100
- Crd Id
- CRD42020216021
- Title
- The effect of peppermint oil supplementation in irritable bowel syndrome: a systematic review with meta-analysis of randomised controlled trials
- Review Question
- What are the effects of peppermint oil compared to placebo on symptoms, stool consistency and frequency, and quality of life, in adults with irritable bowel syndrome?
- Study Type Included
- Only randomised controlled trials (including parallel or crossover designs) will be included. Crossover trials will only be included if they have at least a 2 week washout period. If there is not an adequate washout period, data from the first period will be included, if available, otherwise the study will be ineligible.
- Condition Being Studied
- Irritable bowel syndrome of any subtype: diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C), mixed-type (IBS-M), or unspecified (IBS-U).
- Participant
- Trials will be included if they recruited adult participants (aged at least 18 years) with IBS (any subtype) diagnosed based on clinical diagnostic criteria (e.g. Rome I, II, III, and IV criteria, Manning Criteria), or a physician diagnosis. Studies that report they included participants who have other gastrointestinal conditions (e.g. colorectal cancer, inflammatory bowel disease, celiac disease, drug-induced constipation, etc.), alarm symptoms (e.g. rectal bleeding or unintentional weight loss), history of major abdominal surgery or radiotherapy interfering with GI function, will be excluded if mentioned. Only studies that were undertaken in a community or outpatient setting will be included. There are no other restrictions for age, gender or ethnicity.
- Animal
- Human Disease Modelled
- Intervention
- Trials will be included if their intervention includes peppermint oil. Oral supplementation of peppermint oil will be eligible (e.g. as capsule, liquid formula, tablets, fortified food forms, etc.) as long as the control group is such that the effect of peppermint oil alone can be isolated. All doses of peppermint oil supplementation will be included in the study. Multiple intervention arms (e.g. different doses of peppermint oil compared with placebo) will be eligible. Studies of fresh or dried peppermint (i.e. not oil) will be excluded. Furthermore, studies with a treatment duration of less than 2 weeks will be excluded.
- Comparator Control
- Trials will be included if they use an appropriate placebo as a control to isolate the effects of the peppermint oil alone. Trials that use fortified foods or drinks as an intervention will be eligible as long as the comparator is the same food or drink without the peppermint oil. Studies which contain multiple study arms, the peppermint oil and placebo arm will be isolated and will be included in the study.
- Main Outcome
- Eligible studies will measure at least one of the following outcomes: 1. Gastrointestinal symptoms: a. Dichotomous symptom response (e.g. numbers with adequate/satisfactory relief of symptoms); b. Incidence and severity of gastrointestinal symptoms (e.g. abdominal pain, discomfort, bloating, cramping, belching, nausea, and urgency); c. Integrative symptom scores summarising a range of gastrointestinal symptoms (e.g. IBS-SSS); 3. Stool frequency (e.g. retrospective recall, prospective stool diaries, prospective stool collection); 4. Stool consistency (e.g. the Bristol Stool Form Scale, prospective stool diary, prospective stool collection, retrospective diary); 6. Quality of life (e.g. Irritable Bowel Syndrome Quality of Life, etc.); 7. Anxiety and depression (e.g. Generalized Anxiety Disorder-7); 8. Adverse events: as reported in the individual trials. Measures of effect Odds ratio, relative risk, number needed to treat, standardised mean difference, mean difference.
- Outcome Measure
- Additional Outcome
- None. Measures of effect Not applicable.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Abdominal Pain; Adult; Defecation; Dietary Supplements; Feces; Humans; Irritable Bowel Syndrome; Peppermint Oil; Phytotherapy; Plant Oils; Quality of Life; Signs and Symptoms, Digestive; Treatment Outcome
- Contact
- Margarita Orlova [email protected]
- Organisational Affiliation
- King's College London http://www.kcl.ac.uk/index.aspx
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2020-11-03
- Registration Date
- 2020-11-03
- Anticipated Start Date
- 2020-11-09
- Anticipated Completion Date
- 2020-12-18
- Title Cn
- 薄荷油补充剂对肠易激综合征的效果：随机对照试验的系统评价与Meta分析
- Title En
- The effect of peppermint oil supplementation in irritable bowel syndrome: a systematic review with meta-analysis of randomised controlled trials
- Bilingual Status
- complete